发明授权
- 专利标题: Controlled absorption pharmaceutical formulation
- 专利标题(中): 受控吸收药物制剂
-
申请号: US930138申请日: 1986-11-12
-
公开(公告)号: US4826688A公开(公告)日: 1989-05-02
- 发明人: Donald E. Panoz , Edward J. Geoghegan
- 申请人: Donald E. Panoz , Edward J. Geoghegan
- 申请人地址: IEX Athlone
- 专利权人: 501 Elan Corporation PLC.
- 当前专利权人: 501 Elan Corporation PLC.
- 当前专利权人地址: IEX Athlone
- 优先权: IEX2842/85 19851113
- 主分类号: A61K9/30
- IPC分类号: A61K9/30 ; A61K9/22 ; A61K9/50 ; A61K31/49 ; A61K9/52
摘要:
A controlled absorption quinidine formulation for oral administration comprises a pellet having a core of quinidine or a pharmaceutically acceptable salt thereof in association with an organic acid and optionally other excipients, and an outer membrane which permits release of quinidine in an aqueous medium at a controlled rate which is substantially pH independent. The pellet has a dissolution rate in vitro, which when measured in a Basket Assembly according to U.S. Pharmacopoeia XXI at 37.degree. C. and 75 r.p.m. is not more than 15% after one hour of measurement. Not more than 50% of the total quinidine is release after a total of 4 hours of measurement, not more than 80% is released after a total of 8 hours of measurement and not less than 90% release is achieved after a total of 24 hours.
公开/授权文献
信息查询